Cargando…
Dedifferentiated endometrioid adenocarcinoma with trophoblastic components: Prolonged remission after treatment with bleomycin, etoposide, and cisplatin
Dedifferentiated endometrial adenocarcinoma (DEAC) with trophoblastic components is a rare neoplasm with an aggressive behavior and a poor prognosis. Only seven cases have been reported in the literature. We present a 61-year-old patient who was diagnosed with Stage IB dedifferentiated endometrioid...
Autores principales: | Martin, Alexa K., Jackson, Elizabeth G., Edwards, Henry D., Stany, Michael P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103773/ https://www.ncbi.nlm.nih.gov/pubmed/32258333 http://dx.doi.org/10.1016/j.gore.2020.100562 |
Ejemplares similares
-
Dedifferentiated endometrioid adenocarcinoma with trophoblastic components and elevated serum alfa-fetoprotein: A case report and literature review
por: Cai, He, et al.
Publicado: (2018) -
Real-World Study of Cisplatin, Etoposide, and Bleomycin Chemotherapy Regimen in Gestational Trophoblastic Neoplasia
por: Wang, Ming, et al.
Publicado: (2021) -
Dedifferentiated endometrioid adenocarcinoma: An under-recognized but aggressive tumor?()
por: Wu, Emily S., et al.
Publicado: (2013) -
Dedifferentiated endometrioid adenocarcinoma; clinicopathologic and immunohistochemical features of five cases
por: Yiğit, Seyran, et al.
Publicado: (2018) -
Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604)
por: Cafferty, Fay H., et al.
Publicado: (2020)